SynthesisFrontiers in immunology2026
Emerging CAR-Treg and regulatory T cell therapies for inflammatory bowel diseases: a systematic review of a new era of treatment.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammatory bowel disease (IBD) is a chronic immune-mediated disorder characterized by dysregulated mucosal immunity. Despite major advances in therapies, a high proportion of patients do not achieve or sustain remission. Cellular immunotherapies have emerged as a mechanistically distinct therapeutic strategy with potential relevance for refractory disease. In the present paper, the authors aim to evaluate the rationale and current evidence supporting chimeric antigen receptor (CAR)-engineered immune cells and regulatory T (Treg)-cell-based therapies in IBD. Preclinical studies and early translational data support biological plausibility and feasibility of these therapies. However, available human evidence remains limited, with sparse clinical experience and short follow-up. Methods: A systematic review was conducted according to PRISMA guidelines. Search was performed in PubMed and EMBASE databases from inception to February 2026 including terms like "IBD", "CAR-T", "CAR-Treg" and "Treg therapy" among others. Eligible studies included preclinical, translational and clinical reports evaluating CAR-engineered immune cells in IBD models. Results: A total of 11 studies met the inclusion criteria after the screening and were included in the review. CAR-Treg technologies build upon advances achieved with conventional CAR-T cells in oncology and enable antigen-specific immune regulation rather than cytotoxicity. Preclinical studies and early translational data support biological plausibility and feasibility. However, available human evidence remains limited, with sparse clinical experience and short follow-up. Major unresolved issues include cellular persistence, phenotypic stability (particularly for Tregs), optimal antigen selection, manufacturing scalability, and long-term safety. Conclusions: Cellular immunotherapies represent a promising but still investigational therapeutic paradigm in IBD. Robust clinical trials with standardized endpoints and long-term safety monitoring are needed before their clinical adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.